Kornimate/medical-research-clean huggingface dataset:
perioperative sdd to prevent infectious complications after esophagectomy

Conditions: Esophageal Cancer

Summary: the primary aim of the persuader-trial is to evaluate the effect of sdd on infectious complications after esophagectomy, focussed on the prevention of pneumonia

esophagectomy is a complex surgical procedure, associated with significant morbidity and mortality rates. most postoperative complications are caused by infections (10-30%). these are thought to arise from (micro-)aspiration of bacteria residing in the oropharyngeal and gastrointestinal (gi) tract, leading to (respiratory) infections. selective decontamination of the digestive tract (sdd) is a prophylactic antibiotic strategy that aims to prevent postoperative infections. pathogenic aerobic gram-negative rods and yeasts tract are reduced, while anaerobic, protective microbiota are preserved. sdd has been shown to lower the risk for respiratory infections in an intensive care setting. establishing sdd as effective addition to the standard care of esophagectomy patients is expected to increase their chance of survival.

Eligibility criteria:
inclusion criteria: * diagnosis of primary esophageal adenocarcinoma or squamous cell carcinoma (ct1b-4a,n0-3,m0) in the mid or distal esophagus or at the level of the gastro-esophageal junction scheduled for undergoing transthoracic esophagectomy with curative intent or for esophageal reconstruction with a gastric or jejunal interposition * age ≥ 18 years, * able to give written informed consent. exclusion criteria: * patients planned for rescue surgery, * patients planned for colonic interposition, * known or suspected pregnancy, * patients who have undergone upper gi surgery within 30 days before randomization, * unable to understand the study information, study instructions and give informed consent. * patients enrolled in a trial that would interact with the intervention * patients with a known allergy, sensitivity, or interaction to investigational medicinal product. * patients with known/documented colonization of enterobacteriaceae and or pseudomonas aeruginosa that are resistant to both tobramycin/gentamicin and to carbapenem antibiotics * patients undergoing cvvh. * patients with documented chronic renal failure (gfr \< 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis, * women of childbearing potential at risk of pregnancy, not using adequate contraception, * patients with the inability to swallow the sdd * patients with pre-existing degenerative neuromuscular diseases like, but not limited to, myasthenia gravis or parkinson disease).
effects of curcumin on inflammation and oxidative stress in pediatric patients on regular hemodialysis: a randomized, double-blind, placebo-controlled pilot study

Conditions: Pediatric Patients Having Renal Failure and on Regular Hemodialysis

Summary: * the study will be a randomised, double blinded, placebo controlled design. * it will include 2 groups : trial group and placebo group * patients in both groups are children on regular hemodialysis * the patients in the trial group will receive curcumin capsule 1 gm for 3 months , and the placebo group will receive a placebo capsule for 3 months * all patients will be evaluated clinically, and laboratory at baseline, at 3 months after end of supplementation.


Eligibility criteria:
inclusion criteria: * male or female pediatric patients with weight of at least 30 kilograms. * undergoing regular hemodialysis for at least 6 months. exclusion criteria: * bleeding disorders. * chronic liver disease. * diabetes mellitus. * autoimmune diseases. * receiving drugs that are contraindicated, or have major interactions with curcumin, and can't be discontinued or replaced. * receiving corticosteroids, or immune-suppressants. * patients taking any antioxidant supplements including vitamin e, ascorbic acid, omega -3 fatty acid, or l-carnitine within 3 months prior to enrollment in our study.
slsmds natural history study

Conditions: Pearson Syndrome; Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)

Summary: the single large-scale mtdna deletion sydrome: natural history study (ps-nhs) aims to collect data on standardized clinical outcomes, store data on the champ foundation registry (cfr) and make this data available to researchers, clinicians, and industry partners who are studying slsmds to answer questions regarding the disease, including its causes, potential treatments, and other topics. a secondary aim is to analyze the data to understand research questions relating to the natural history of slsmds.

this study is a prospective, observational, and longitudinal study intended to track the course of pearson syndrome and single large scale mitochondrial dna deletion syndromes (slsmds) to identify demographic, genetic, environmental, and other variables that correlate with the diseases development and outcomes. if available, retrospective clinical data may be accessed and used in analyses as well. the ps-nhs will be conducted at two center of excellence sites: the cleveland clinic and children's hospital of philadelphia (chop). all ps-nhs data will be entered and stored on the cfr. the cfr exists entirely online.

Eligibility criteria:
inclusion criteria: * have an active account on the champ foundation registry (cfr) or be willing to create an account on the cfr. * must have a genetic diagnosis of a single large-scale mitochondrial dna deletion and must upload their genetic report to the cfr. * have a clinical diagnosis or history of pearson syndrome or have symptom onset prior to five years of age and a genetic diagnosis of a single large-scale mitochondrial dna deletion or in the opinion of the principal investigator the participant is suitable for participating in this study based on clinical presentation. participants may be of any age or gender, and originate from any country.
quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial

Conditions: Esophageal Neoplasms

Summary: the purpose of this study is to compare the results of preoperative chemotherapy and radiation followed by surgery to surgery followed by postoperative chemotherapy and radiation for esophageal cancer.

patients will be randomized to neo-adjuvant or adjuvant treatment. quality of life questionnaires will be completed every 2 months up to 1 year.

Eligibility criteria:
inclusion criteria: * histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (\> 20 cm from the incisors) or gastroesophageal junction are included. * no distant metastases (m0). * patients will be stratified by stage (clinical n0 versus clinical n1), and surgeon. * patients with tumours within 3 cm distal spread into gastric cardia as detected by esophagogastroscopy. * resectable mediastinal nodes are eligible. * no prior chemotherapy for this malignancy. * no prior radiotherapy that would overlap the field(s) treated in this study. * patients with other malignancies are eligible only if \> 5 years without evidence of disease or completely resected or treated non-melanoma skin cancer. * age \> 18 years and able to tolerate tri-modality therapy at the discretion of the treating thoracic surgeon, medical and radiation oncologists. tumours must be resectable after assessment by the thoracic surgeon. exclusion criteria: * cancers of the cervical esophagus (\< 20 cm are excluded). * tumours that have \> 3 cm of spread into cardia of the stomach are considered gastric cancers and are ineligible. * patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy ) proven metastatic supraclavicular nodes are ineligible. * patients with biopsy proven metastatic celiac nodes are ineligible.

Keywords: esophageal carcinoma chemotherapy radiation surgery randomized clinical trial clinical trial radiotherapy
pregabalin treatment and prevention post-herpetic neuralgia

Conditions: Herpetic Neuralgia

Summary: pregabalin is effective on herpetic neuralgia, but whether can prevention post-herpetic neuralgia still need to confirm.

pregabalin has been recommended as the first-line drug for post-herpetic neuralgia (phn) therapy currently due to its efficacy and safety. however,there was no valuable report at present on the clinical efficacy of pregabalin for acute and subacute herpetic neuralgia (shn), expect for a smaller study which included 29 outpatients who had acute zoster pain for a period of 7-1 4 days. and it is not clear whether early application of pregabalin can reduce the incidence of phn. therefore, this study was rational designed to evaluate the efficacy and safety of pregabalin in the treatment of herpetic neuralgia，and follow-up to the 8 months, evaluation whether impacting the accidence of phn. it is the first time in the international that treating acute herpetic neuralgia (ahn) and shn with pregabalin as a large sample size clinical trial. the results of this study will be great significance for guiding the clinical medication.

Eligibility criteria:
inclusion criteria: 1. pain occurs within 90 days of rash onset 2. numerical rating scale (nrs) greater than 50 mm exclusion criteria: 1. patient with nervous system disorders which impair completing the pain diaries 2. patient with history of illicit drug or alcohol abuse within the last 2 years

Keywords: herpetic neuralgia post-herpetic neuralgia pregabalin
comparative analysis of filmed sequences for the assessment of discomfort in atopic dermatitis of infants under 6 months of age

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad) is an frequent chronic and itchy inflammatory dermatitis which concern about 20% of pediatric population with a revelation usually toward 3-6 months of live. however, there are very few data about the prevalence of pruritus of young infants and about the discomfort linked with it. while the skin and the nervous system of young infants (under 6 month) are competent in pruritus experiment, the acquisition of conscious and deliberate motor ability allowing specific scratching of the body parts which are affected is possible only from 6 month. thus, the diagnosis of ad intensity and the assesment of the potential associated discomfort are hard. at the present time, the diagnosis and the assesment of pruritus of children are based on a hetero-assesment via scales which are not applicable for infants under 6 month. the visual scale "numeric rating scale" validated in adult population seems to be the most specific to assess ad severity. in pediatric population, the use of "eppendorf itch questionnaire" and the american version of "childhood atopic dermatitis impact scale" are recommended. alternatives to clinic and subjective scoring of pruritus severity are described via actigraphy. thus, a strong statistic correlation have been demonstrated between a nocturne measure of motor activity of wrist, as a reflect of the intensity of pruritus, and infra-red video analysis. but, once again, the technic is not adapted to young infants because of the absence of conscious and oriented motor ability and as a result of less organised sleep/wake cycle. in order to improve young infants' (under 6 month) care, the analysis of their behaviours with ad seems to be necessary to better identify a discomfort of these patients.


Eligibility criteria:
atopic dermatitis patients : inclusion criteria: * young infant under 6 month * patient with ad (scorad between 25 and 50 for moderate ad and \> 50 for severe ad) * informed consent of the patient's parents healthy patients : inclusion criteria: * young infant under 6 month * free of any pathology * informed consent of the patient's parents exclusion criteria (for every patients) : * acute intercurrent disease * severe malformation * underage parents or parent unable to give their consent
efficacy and safety of deferasirox in patients with myelodysplastic syndrome and transfusion-dependent iron overload

Conditions: Myelodysplastic Syndromes; Transfusion Dependent Iron Overload

Summary: the purpose of this study is to investigate the effects of iron chelation using deferasirox in low and int-1 risk (referring to the international prognostic scoring system, ipss) mds patients who show signs of iron overload due to repeated blood transfusions. this trial is not recruiting patients in the united states.


Eligibility criteria:
inclusion criteria: * mds patients presenting with low or intermediate-1 ipss risk and transfusional iron overload * patients of either gender and age ≥ 18 years * history of at least 20 units of red blood cell transfusions or 100ml/kg of prepacked red blood cells (prbcs) * patients can be either naïve to iron chelation or have had prior treatment with deferoxamine (dfo) or deferiprone (l1) * females of childbearing potential must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months. exclusion criteria: * non-transfusion related iron overload * treatment with deferasirox (icl670) before study start * patients with a concomitant malignant disease * patients with out of range lab values * history of nephrotic syndrome * patients with a previous history of clinically relevant ocular toxicity related to iron chelation * systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment * patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days * any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. * patients with active uncontrolled infectious disease * pregnancy or breast feeding other protocol-defined inclusion/exclusion criteria may apply.

Keywords: myelodysplastic syndrome mds iron overload chelation chelators icl670 deferasirox serum ferritin lic transfusional hemosiderosis refractory anemia ra refractory anemia with ringed sideroblasts rars blood transfusions mydelodysplastic syndrome(s)
evaluation of the improvement of independence by the resumption of a significant activity such as a cooking workshop in adult patients with stroke benefiting from traditional rehabilitation

Conditions: Stroke

Summary: a non-randomized, monocentric, pilot study comparing the level of independence for each individual with significant resumption of activity in adult patients with stroke


Eligibility criteria:
inclusion criteria: * patient older than 18 years old * primary stroke or recurrence on stroke having no previous sequelae * stroke older than 3 weeks * ability to understand treatment and sufficient motivation * problem activity indicated in cmop (canadian measure of occupational performance) * barthel index \> 60 * patient who received oral and written information about the protocol and who did not show opposition to participate in the study exclusion criteria: * dermatological pathology with wounds on the unhealed upper limbs * patient in contact and droplet isolation * a psychiatric history requiring hospitalization in specialized settings for more than 2 months * any condition that may limit participation or interfere with analysis of results
environmental and genetic risk factors for pediatric multiple sclerosis

Conditions: Pediatric Multiple Sclerosis

Summary: the purpose of this study is to better understand multiple sclerosis (ms) in children and adolescents, to learn if it differs from adult ms and to investigate if genes or environmental exposures or a combination of both put children and adolescents at risk for getting ms.

the overall goal of this project is to determine whether well-established environmental and genetic risk factors for adult onset ms play an important role in susceptibility to pediatric-onset ms. our study design is based on the hypothesis that genetic influences, specifically variation at hla-drb1 and other confirmed non-mhc ms loci, as well as environmental exposures including ebv infection and tobacco smoke, contribute to disease risk. in addition, we will also examine the relationship between serum levels of 25(oh) vitamin d3 and prior vitamin d status, and risk for pediatric onset ms. finally, we will investigate whether specific g x e, and other multivariable relationships influencing risk exist for pediatric-onset ms. there are 16 collaborating sites other than ucsf that will enroll cases and controls for this study.

Eligibility criteria:
children are eligible for this study as cases if: * they have ms or clinically isolated syndrome (cis): * ms: as defined by the 2010 mcdonald criteria for diagnosis of ms (polman 2010), * cis: a first demyelinating event indicating high risk for ms (i.e., one clinical event involving the spinal cord, the optic nerve, the brainstem or cerebellum, or occasionally the hemispheres) and at least 2 silent t2 bright areas on a brain or spinal cord mri (at least one must be in the brain); and * they are three years of age or older; and * disease onset occurred before 18 years of age. patients are not eligible for study participation if: * disease onset occurred more than 4 years prior to the opportunity to enroll; or * they have had an organ transplant; or * they are known to have neuromyelitis optica (nmo). children are not eligible to participate as pediatric controls if: * they are two years of age or younger; or * they are 22 years of age or older; or * they are known to have ms or another demyelinating disease (for example, neuromyelitis optica or acute disseminated encephalomyelitis); or * they have a biological family member who has been enrolled as a control; or * they have an immediate, biological family member (parent/sibling) who has been diagnosed with ms; or * they have an autoimmune disorder (except asthma or eczema); or * they have had an organ transplant; or * they have a chronic neurological condition with major disability (this does not include, for example, migraine, controlled seizures, and mild learning disabilities such as add or adhd).

Keywords: pediatric multiple sclerosis relapsing remitting multiple sclerosis clinically isolated syndrome demyelinating disease
the effects of virtual colonoscopy on intraocular pressure

Conditions: Intraocular Pressure Disorder

Summary: our trial examined the intraocular pressure measurements differences, before and after virtual colonoscopy examination.

glaucoma is a complicated disease in which damage to the optic nerve leads to progressive, irreversible vision loss. glaucoma is the second leading cause of blindness and associated with elevated intraocular pressure (iop) as a major risk factor. iop is influenced by many factors, including ethnicity, heredity, various chemical substances (existing body and external body like drugs), physical changes (postures, neural and vascular autoregulation) and more. virtual colonoscopy is a common screening test for the early detection and diagnosis of colon cancer. the test is performed by computed tomography (ct) after inflating the colon with carbon dioxide (co2) gas. the procedure is performed by inserting a foley catheter through the anus. as a result of gas inflating of the bowel, consequently, there is an increase in the abdominal pressure. raising intra-abdominal pressure may cause a rise in intraocular pressure. the aim of this research is to examine the changes in iop before and after the virtual colonoscopy, with the aim to improve the understanding of the relationship between intra-abdominal pressure and iop. the study will include 100 patients, men and women, that are scheduled for virtual colonoscopy test both in a hospital and in ambulatory.

Eligibility criteria:
inclusion criteria: * participants: men and women. * age ≥ 18 years. * directed by a gastroenterologist to examine colonoscopy for diagnosing colon pathology (either screening, follow-up routine or after surgery). * patients who want to participate which are able to understand and sign, an informed consent to participate in research. exclusion criteria: * exclusion recruitment criteria: * family history of glaucoma first-degree relatives. * patients suffering from known eye diseases, except for refractive disorders, strabismus or amblyopia, and do not take any eye care on a regular basis. * patients with a known allergy for localin drops. * patients who do not want to participate or are unable to understand or sign an informed consent to participate in research. exclusion criteria from the study: * the researcher doctor may remove a participant from the study if he impressed, of strong health impairments resulting from the research.

Keywords: glaucoma intraocular pressure colonoscopy virtual colonoscopy valsalva
impact of septal vs apical pacing on right and left ventricular performance

Conditions: Heart Block; Sick Sinus Syndrome; Atrioventricular Block; Ventricular Dysfunction

Summary: the study aims to use cardiac mri scans and analysis techniques to evaluate differences in cardiac function after 12 months of pacing in patients with pacing leads placed in different positions within the right ventricle (apically or septally).

prolonged pacing from the right ventricular (rv) apex has been shown to be associated with progressive left ventricular (lv) dysfunction. this has led to an interest in alternative right ventricular pacing sites. only very few studies investigated the effect of alternative right ventricular pacing sites using three dimensional imaging. using cardiac mri volumetric left- and right ventricular analysis and three-dimensional reconstruction is more accurate compared to trans-thoracic echocardiogram. st. jude medical has developed a mri conditional pacemaker system enabling for the first time to investigate alternative pacing sites using cardiac mri. patients already implanted with an mri conditional pacemaker system from st. jude medical will be enrolled in that study and subdivided into 4 groups (right ventricular pacing lead positioned apically or septally subdivided in patients paced for \<50% of time or 50% or more). all patients will undergo cardiac mri at enrollment and again 12 months later. patients paced \<50% of the time will undergo cardiac mri with and without pacemaker stimulation at both visits.

Eligibility criteria:
inclusion criteria: * have been implanted with an accent mri pacemaker and tendril mri leads. * have an rv lead implanted apically (group a) or septally (group b) * are rv paced for \<50% of the time (groups a2 and b2) * are rv paced for \> 50% of the time (groups a1 and b1) * are ≥ 18 years of age. * are able to provide written informed consent. * are willing and able to comply with the prescribed follow-up tests and schedule of evaluations. exclusion criteria: * have permanent atrial fibrillation with preserved intrinsic conduction * have a non-mri compatible device or material implant (e.g., intracranial aneurysm clip, non-mri compatible devices or material, metals or alloys, etc.). * have a lead extender, plug or adaptor. * do not have an rv lead implanted apically or septally. * are eligible for groups a1 or b1 but appropriate group already has 20 patients enrolled. * are eligible for groups a2 or b2 but appropriate group already has 5 patients enrolled * are currently participating in another device or drug investigation which includes an active treatment arm. * are pregnant or planning to become pregnant during the duration of the study. * have a life expectancy of less than 12 months from screening due to any life-threatening condition. * are contraindicated for an mri scan due to any other reason.